Welcome to LookChem.com Sign In|Join Free
The company logo of Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Free supplier Enterprise Certification

Free
supplier
8th
years

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Business Type:Lab/Research institutions

Audited Supplier

Main Products:
Year Established:
2017
Home>>Products>>Granisetron

Products Categories

Product Certification&
Enterprise Certification

More Detail

Chengdu Henghui Pharmaceutical Co., Ltd.(expird)

Country: China (Mainland)

Business Type:Lab/Research institutions

Granisetron

CAS NO.109889-09-0

  • Min.Order: 10 Gram
  • Payment Terms:
Contact Supplier

Product Details

Keywords

  • Granisetron
  • high purity
  • best price

Quick Details

  • ProName: Granisetron
  • CasNo: 109889-09-0
  • Molecular Formula: C18H24N4O
  • Appearance: white powder
  • Application: For laboratory use only- not intended ...
  • ProductionCapacity: 1 Kilogram/Month
  • Purity: ≥ 99%
  • Storage: room temperature
  • Transportation: by air
  • LimitNum: 10 Gram

Superiority

We are a CRO company, and our Research and Development team is consisted of PhDs and Masters in chemistry and pharmacy.

We are committed to protect our customer’s privacy with the highest level of ethical standard. Our dedicated team will follow up on every order and provide instant feedback on the status to our customer.

We stand behind our product by providing a complete QA report. The test data of customer order can be provided upon request.

We make our efforts to offer customer innovative, customized, high-quality service.

Our custom manufacturing encompasses everything from pharmaceutical intermediates to API.

 

 

 

Details

Granisetron is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy. IC50 Value: 17uM (GR reduced 5-HT-evoked contractions) [1] Target: 5-HT3 receptor in vitro: In rat forestomach GR reduced 5-HT-evoked contractions at IC50 17 /- 6 uM. In isolated rabbit heart, GR 0.003-0.03 nM dose-dependently reduced s-HT tachycardia; at high levels GR reduced submaximal and maximal responses to 5-HT . in vivo: Leukocyte accumulation was dose-dependently inhibited by granisetron both at 6 and 72 h after induction of inflammation. Granisetron increased PGE(2) level at a lower dose (50 microg/pouch) but higher doses (100 and 200 microg/pouch) inhibited the release. At the same time, TNFalpha production was decreased by the lower dose and increased by higher doses of granisetron in a reciprocal fashion. The GTDS displayed non-inferiority to oral granisetron: complete control was achieved by 60% of patients in the GTDS group, and 65% in the oral granisetron group (treatment difference, -5%; 95% confidence interval, -13-3). Both treatments were well tolerated, the most common adverse event being constipation.  Clinical trial: Effect of External Heat on a Transdermal Granisetron Patch in Pharmacokinetics (PK) of Healthy Subjects.

Hot Product